Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gemma Medcalf

- PMLiVE

Wilmington Healthcare appoints new Account Director

Healthcare intelligence provider Wilmington Healthcare, which incorporates Binley’s, NHiS, Wellards and HSJ, has strengthened its salesforce with the appointment of Gareth Thurston as Account Director.

Wilmington Healthcare

- PMLiVE

Keytruda adds stomach cancer to growing list of US approvals

FDA clears the drug as a third-line option after chemotherapy

- PMLiVE

Axon welcomes four new hires to its PR and med comms teams

Christopher Goddard, Lisa Seukeran, Aggie Popowicz and Priya Talluri join the agency

- PMLiVE

Pfizer spins out SpringWorks Therapeutics biotech

Former Pfizer VP Lara Sullivan takes the helm at the newly-formed company

- PMLiVE

Janssen wins European approval for Symtuza

European Commission approves the drug to treat HIV-1

- PMLiVE

Paolo Carli appointed as head of MEA at Merck

He will be responsible for leading commercial operations

Perspective on biotech

In this supplementary issue of Perspective, we reveal the emerging technologies taking the biotech world by storm and ask if the definition of a biotech organisation needs updating.

Blue Latitude Health

- PMLiVE

Lucid CEO discusses communication excellence in a multimedia world

“The two words 'information' and 'communication' are often used interchangeably, but they signify quite different things. Information is giving out; communication is getting through,” Sydney J. Harris, a renowned Anglo-American...

Lucid Group Communications Limited

- PMLiVE

Can big data give medical affairs an edge in strategic planning?

Teams can better identify, and engage with, KOLs while also measuring their endeavours

What will the NHS’s Capped Expenditure Process (CEP) mean for pharma?

Paul Midgley, Director of NHS Insight at Wilmington Healthcare, explains how pharma should tailor its approach

Wilmington Healthcare

Roche Basel Switzerland

Roche’s Actemra/RoActemra receives new European approval

EU regulators also pass the Swiss pharma firm’s Gazyvaro

- PMLiVE

Versartis crashes as VELOCITY trial veers off track

The US biotech's somavaratan proved inferior to Pfzier’s Genotropin

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links